OR WAIT null SECS
Colorcon’s new suite will provide clients with capabilities to develop prototype tablets or capsule dosage forms when API quantity is limited or the API potency requires a higher level of protection.
Colorcon announced on May 18, 2021 that it has added a new containment suite to its global headquarters in Harleysville, Pa. to further expand its technical capabilities.
According to a company press release, the new suite will provide clients with capabilities to develop prototype tablets or capsule dosage forms when API quantity is limited or the API potency requires a higher level of protection.
“Investing in this facility demonstrates Colorcon’s continued commitment to supporting pharmaceutical development in North America, reducing our customer’s time to market, and reflects our dedication to providing unparalleled products and services,” said Kurt Fegely, managing director, Colorcon Americas, in the press release. “We can now offer a complete cycle starting from the customer’s API, all the way to a finished coated dosage form within our facilities and provide prototypes ready for customer evaluation.”
“Many of our customers, especially in early development phase, work with very small quantities of active ingredients, which can have unknown safety profiles and can also be extremely costly and limited in availability,” added Charlie Cunningham, technical director, Colorcon, in the press release. “Our investment in the best equipment enables us to produce tablets and capsules with milligrams of active product in the safest of conditions.”